Literature DB >> 21708957

Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.

Sophia Platonova1, Julien Cherfils-Vicini, Diane Damotte, Lucile Crozet, Vincent Vieillard, Pierre Validire, Pascale André, Marie-Caroline Dieu-Nosjean, Marco Alifano, Jean-François Régnard, Wolf-Herman Fridman, Catherine Sautès-Fridman, Isabelle Cremer.   

Abstract

Both the innate and adaptive immune systems contribute to tumor immunosurveillance in mice and humans; however, there is a paucity of direct evidence of a role for natural killer (NK) cells in this important process. In this study, we investigated the intratumoral phenotypic profile and functions of NK cells in primary human tumor specimens of non-small cell lung carcinoma (NSCLC). We used in situ methods to quantify and localize NK cells using the NKp46 marker and we characterized their phenotype in blood, tumoral, and nontumoral samples of NSCLC patients. Intratumoral NK cells displayed a profound and coordinated alteration of their phenotype, with a drastic reduction of NK cell receptor expression specifically detected in the tumoral region. According to their altered phenotype, intratumoral NK cells exhibited profound defects in the ability to activate degranulation and IFN-γ production. We found that the presence of NK cells did not impact the clinical outcome of patients with NSCLC. Finally, we showed that tumor cells heterogeneously express ligands for both activating and inhibitory NK receptors. Taken together, our results suggest that the NSCLC tumor microenvironment locally impairs NK cells, rendering them less tumorcidal and thereby supportive to cancer progression.

Entities:  

Mesh:

Year:  2011        PMID: 21708957     DOI: 10.1158/0008-5472.CAN-10-4179

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  188 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

Review 2.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

3.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

Review 4.  Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression.

Authors:  Peter J Chockley; Venkateshwar G Keshamouni
Journal:  J Immunol       Date:  2016-08-01       Impact factor: 5.422

5.  The breast tumor microenvironment alters the phenotype and function of natural killer cells.

Authors:  Tamara Krneta; Amy Gillgrass; Marianne Chew; Ali A Ashkar
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

6.  NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome.

Authors:  Sylvie Rusakiewicz; Gaetane Nocturne; Thierry Lazure; Michaela Semeraro; Caroline Flament; Sophie Caillat-Zucman; Damien Sène; Nicolas Delahaye; Eric Vivier; Kariman Chaba; Vichnou Poirier-Colame; Gunnel Nordmark; Maija-Leena Eloranta; Per Eriksson; Elke Theander; Helena Forsblad-d'Elia; Roald Omdal; Marie Wahren-Herlenius; Roland Jonsson; Lars Rönnblom; Joanne Nititham; Kimberly E Taylor; Christopher J Lessard; Kathy L Moser Sivils; Jacques-Eric Gottenberg; Lindsey A Criswell; Corinne Miceli-Richard; Laurence Zitvogel; Xavier Mariette
Journal:  Sci Transl Med       Date:  2013-07-24       Impact factor: 17.956

7.  Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Authors:  Laetitia Fend; Sylvie Rusakiewicz; Julien Adam; Bérangère Bastien; Anne Caignard; Meriem Messaoudene; Christina Iribarren; Isabelle Cremer; Aurélien Marabelle; Christophe Borg; Michaela Semeraro; Luc Barraud; Jean-Marc Limacher; Alexander Eggermont; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 8.  Immunotherapy for lung cancer: advances and prospects.

Authors:  Li Yang; Liping Wang; Yi Zhang
Journal:  Am J Clin Exp Immunol       Date:  2016-03-23

9.  TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.

Authors:  Sarah S Donatelli; Jun-Min Zhou; Danielle L Gilvary; Erika A Eksioglu; Xianghong Chen; W Douglas Cress; Eric B Haura; Matthew B Schabath; Domenico Coppola; Sheng Wei; Julie Y Djeu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-28       Impact factor: 11.205

10.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.